gotta run out the door, but...... the Novartis molecules have names!
<TABLE>
<CAPTION>
DEVELOPMENT COMMERCIAL
PROGRAM THERAPEUTIC TARGET STATUS(1) RIGHTS
------- ------------------ ----------- ----------
<S> <C> <C> <C>
HUMAN RECEPTOR/ION CHANNEL SUBTYPE TECHNOLOGY
nAChR Agonists
SIB-1508Y Parkinson's Disease Phase 2 clinical trials Meiji/SIBIA
SIB-1553A Alzheimer's Disease, Phase 2 clinical trial SIBIA
Attention Deficit
and Hyperactivity
Disorder (ADHD),
Schizophrenia
SIB-3182 Alzheimer's Disease, Pre-clinical SIBIA
Attention Deficit
and Hyperactivity
Disorder (ADHD),
Schizophrenia
Other Series Pain, Schizophrenia, Discovery/Leads identified SIBIA
Depression
EAAR Ligands
CGP 79397 Epilepsy Pre-clinical Novartis/SIBIA
CGP 80887 Pain Pre-clinical Novartis/SIBIA
Other Series Pain, Anxiety, Discovery/Leads identified SIBIA
Schizophrenia,
Neurodegenerative
Diseases
VGCC Antagonists
Compound Series Neuropathic and Leads identified SIBIA
Chronic Pain
HUMAN PROTEASE TECHNOLOGY
A(BETA) Inhibitors Alzheimer's Disease Pre-clinical Bristol-Myers Squibb/
SIBIA
Apoptosis Modulators Stroke, Brain Discovery/Leads identified SIBIA
Injury,
Neurodegenerative
Diseases |
